Irritable bowel syndrome
Conditions
Interventions
Rifaximin group:Rifaximin
Placebo group:Placebo
Control group:None
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 to 65 years old; 2. No abnormal findings in routine blood test, blood chemical test and stool routine test; 3. No abnormal findings in abdominal ultrasonography examination and colonoscopy/colonic barium enema.
Exclusion criteria
Exclusion criteria: 1. Malignant tumors; 2. Severe heart, liver, lung, kidney, hematological, endocrine, nervous system or autoimmune diseases; 3. Multiple peripheral vascular disease; 4. Infectious diseases of respiratary, digestive or urinary system; 5. Abdominal surgery; 6. Schizophrenia; 7. Women in pregnancy or who are lactating; 8. Subjects who had taken probiotics, prebiotic, antibiotics or antidepressants within the last 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of abdominal symptms;small intestinal bacterial overgrowth;Gastrointestinal Symptom Rating Scale-IBS;Severity of anxiety and depression;Quality of life;Defecation evaluation;Gut microbiota structure;Fecal short-chain fatty acids levels;Dietary survey;Intestinal membrane permeability evaluation;cytokines levels;Visceral sensitivity; | — |
Countries
America
Contacts
Public ContactLiping Duan
Peking University Third Hospital
Outcome results
None listed